UNSPSC 51384630: Oxyphenbutazone piperazine

This classification denotes a nonsteroidal antiinflammatory drug C19H20N2O3.C4H10N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 86B165MRR5, chemically known as 3,5-pyrazolidinedione, 4-butyl-1-(4-hydroxyphenyl)-2-phenyl-, compd. with piperazine (1:1), but more generally known as oxyphenbutazone piperazine, which bears US NIH Compound Identifier 72941570. European Medicines Agency schedules Oxyphenbutazone piperazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03593MIG.

Most nations, for tariff and trade purposes, schedule oxyphenbutazone piperazine under HS 29331990 and SITC 51571. As of Q4 2014, OXYPHENBUTAZONE PIPERAZINE remains US FDA's Preferred Term for this commodity. SMILES: CCCCC1C(=O)N(N(C1=O)C2CCC(CC2)O)C3CCCCC3.C1CNCCN1.

UNSPSC 51384630 Oxyphenbutazone piperazine is a Commodity code that shows minimal alignment with recent state and local procurement activity. The code nominally identifies a specific pharmaceutical compound, but the recent solicitations tagged under it involve naloxone, generic multi-source pharmaceuticals, over-the-counter products, and direct-to-manufacturer prescription programs—none of which are oxyphenbutazone piperazine. The work actually being procured under this code identifier spans emergency response supplies (naloxone kits and drug deactivation systems), cooperative purchasing agreements for generic pharmaceuticals and OTC products distributed through authorized wholesalers, and exploratory market research into direct contracting models for pharmacy benefit programs. Issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS), and multi-state cooperative purchasing alliances administered by state procurement offices (Minnesota MMCAP).

Activity is concentrated in Florida, Texas, and Minnesota. Recent opportunities include Seminole County's IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023 (posted June 30, 2026); Minnesota MMCAP's RFP for generic multi-source pharmaceuticals and OTC products with proposals due March 26, 2026; and Texas HHS's Request for Information on direct-to-manufacturer prescription programs posted April 3, 2026. The code appears to be a data-classification error—oxyphenbutazone piperazine does not feature in any of the three recent solicitations. Vendors pursuing state and local pharmaceutical procurement should verify the actual UNSPSC alignment before responding, as the nominal code does not reflect the scope of work being solicited.